New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD
|
|
- Susan Sullivan
- 6 years ago
- Views:
Transcription
1 Viral Targets for HCV New Therapies on the Horizon in Hepatitis C Patients Paul Y. Kwo, MD Sites for development of inhibitors Metalloproteinase Serine protease (trans) Core E E2 NS2 NS3 NS4a/NS4b NS5a/NS5b 5 UTR 3 UTR Helicase Serine protease (cis) RNA polymerase The Three Phases in the Evolution of HCV Therapy 99s and beyond The Empiric Phase The Refinement Phase Viral kinetics Optimal dosing Challenging populations Nonresponders Modifed from : Weisberg IW, Sigal SH, Jacobson IM. Current Hepatitis Reports 27;6:75-82 The Phase of Direct Acting Anti-virals (DAA) Or Specifically Targeted Antiviral Therapy For HCV (STAT-C) Two protease inhibitors show promise in therapy for genotype HCV infection Telaprevir and Boceprevir specifically inhibit the NS3/4A protease of genotype hepatitis C virus Inhibition of NS3/4a blocks polyprotein processing interfering with HCV replication Phase 2 results show both have the potential improve SVR rates Phase 3 results to be presented at AASLD /2 Both therapies will be added to peg interferon and ribavirin HCV Infection and Replication: Targets for Therapy Cell infection Receptormediated binding HCV Entry & uncoating Replication: Majority of new agents in development Translation & post-translational Processing (NS3 protease) polyprotein Nucleus Ribosome structural Nonstructural 5' 3' Replicase HCV RNA (RDRP-Helicase) polymerase 3' 5' Assembly 5' 3' Figure modified from Davis GL. Hepatitis C. In: Schiff s Disease of the Liver, 22. Membrane fusion & secretion Assembly & Secretion Direct Viral Enzyme Inhibitors Potently Suppress Viral Replication: Protease Inhibition HCV RNA Change from Baseline (Log IU/mL) B Study Time (days) Forestier N, et al. Hepatology. 27;46(3): Baseline PEG-IFN alfa-2a + placebo Telaprevir (VX-95) Telaprevir (VX-95) + PEG-IFN alfa-2a
2 Median HCV RNA (Log IU/mL) Resistance Develops Rapidly with Monotherapy Median HCV RNA Over Time Resistance profiles established Study Time (Days) PR48 (control) (n=75) T2/PR2 (n=7) T2/PR24 (n=79) T2/PR48 (n=79) PROVE: Phase II Study Design U.S., Genotype, Treatment Naive Placebo + TVR + TVR + TVR + Peg-IFN Weeks Subjects in the 2- and 24-week TVR-based treatment arms needed to achieve RVR at Week 4 and maintain undetectable HCV RNA (< IU/mL) through the end of their assigned dosing, to end of treatment at Weeks 2 and 24, respectively Placebo Telaprevir 45 mg q8h Telaprevir 75 mg q8h Telaprevir 25 mg q2h Reesink HW, et al. Gastroenterology. 25;28(suppl 2):A-697. Abstract 527. Dosing: Peg-IFN = Peg-IFN alfa-2a 8 µg/week, RBV = RBV, or,2 mg/day, TVR = TVR 75 mg q8h; RVR = rapid virologic response McHutchison. EASL 28 In Vitro Resistance to Protease Inhibitors Cross Resistance Will Occur PROVE : SVR Rates (ITT) C E E2 p7 NS2 NS3 NS4A NS4B NS5A NS5B Telaprevir Boceprevir ITMN-9 BILN-26 V36A/M T54A R55K/T. Lu L, et al. Antimicrob Agents Chemother. (6), Mo H, et al. 25;49 (): Lin C, et al. J Biol Chem 4. Lin C, et al. J Biol Chem. 25;28, Sarrazin C, et al. AASLD. 25. A56S/V/T D68A/V/E V7A S489L 6. Yi M, et al.. 26;28(2): Malcolm BA, et al. 2 th International Symposium on HCV Zeuzem S, et al. AASLD Seiwert SD, et al. DDW Keiffer T, et al. Hepatology, 27;46(3): SVR rate (%) / /7 PR48 T2/PR2 T2/PR24 T2/PR48 One subject in the T2/PR24 arm did not meet RVR criterion, completed 48 weeks of treatment and had an SVR, but was not counted as a responder in this analysis McHutchison. EASL 28 p=.2 p=. 6 48/ /79 Protease (NS3/4A) Inhibitors: Genotype 5 PROVE: Relapse Rates BILN 26 Boehringer Ingelheim Phase Stop- Heart Tox Telaprevir Vertex/Tibotec Phase 3 Boceprevir Schering-Plough Phase 3 ACH-86 Achillion/Gilead Phase Stop- Renal tox ITMN 9/R7227 InterMune/Roche Phase 2 TMC43535 Medivir/Tibotec JJ Phase 2 BI 2335 Boehringer Ingelheim Phase 2 MK79 Merck Phase 2 Relapse rate (%) /35 PR48 33* 3/9 T2/PR2 TVR drives high rates of RVR and low rates of relapse /4 3/5 6 2* T2/PR24 T2/PR48 In the T2/PR48 arm, including only subjects who had an RVR, the relapse rate was % Denominator is the number of subjects with undetectable HCV RNA at completion of assigned treatment duration *Includes subjects who met the RVR criterion and stopped at 2 or 24 total weeks of treatment McHutchison.NEJM 29 2
3 Control SPRINT- Study Design Week 4 Week 28 Week 48 Peg-IFNα2b.5 μg/kg 8-4 mg for 48 wks N=4 PROVE 3: Telaprevir (TVR) + PegIFN ± RBV in Previous Nonresponders/Relapsers Week 2 Week 24 Week 48 PART PART 2 a Lead-in 8-4 mg Peg-IFNα2b 8-4 mg No Lead-in Low Dose RBV Peg-IFNα2b Peg-IFNα2b.5 μg/kg + RBV 8-4mg + Boceprevir 8 mg TID for Peg-IFNα2b.5 μg/kg 8-4 mg + Boceprevir 8 mg TID for Peg-IFNα2b.5 μg/kg 8-4 mg + Boceprevir 8 mg TID for 28 wks Peg-IFNα2b.5 μg/kg 8-4 mg + Boceprevir 8 mg TID for 48 wks Peg-IFNα2b.5 μg/kg 8-4 mg + Boceprevir 8 mg TID for 48 wks Peg-IFNα2b.5 μg/kg 4- mg + Boceprevir 8 mg TID for 48 wks a Part two consisted of 75 patients in US sites, :4 randomization. N=3 N=3 N=7 N=3 N=6 N=59 Patients with HCV GT infection and nonresponse, breakthrough, or relapse with previous peg/ifn therapy (N = 453) Manns et al EASL PegIFN alfa-2a 8 µg/week + RBV -2 mg/day + Placebo (n = 4) TVR 75 mg TID + PegIFN PegIFN (n = 5) TVR 75 mg TID + PegIFN (n = 3) TVR 75 mg TID + PegIFN (n = ) PegIFN PegIFN 24-wk follow-up Nonresponse HCV RNA positive throughout treatment and at end of treatment Relapse HCV RNA negative at end of treatment, but HCV RNA positive during follow-up Breakthrough Initially HCV RNA negative during treatment, but HCV RNA positive by end of treatment All with adequate previous course of PEG/RBV What is the Potential Role of a Lead-in Phase? Achieve steady-state drug levels for Peginterferon and ribavirin May suppress the expansion of pre-existent or selected resistant strains May allow to individualize treatment with PIs High PEG-IFN sensitivity: no PI required Minimum PEG-IFN sensitivity to avoid functional monotherapy % with SVR Prove 3: SVR rates by treatment group and prior response 4/7 and 4/8 with prior breakthrough achieved SVR in T2/PR24 and T24/PR48 groups McHutchison et al NEJM 29 % Patients HCV Negative SPRINT- SVR rates Part 54 b 56 c 67d P/R Control P/R/B P/R/B 48 wks 28 wks f P/R 4 wks P/R/B 48 wks N=4 N=7 N=3 N=3 P/R 4 wks P/R/B N=3 Part 2 a Roche COBAS TaqMan LLD <5 IU/mL; b P =.3; c P =.5; d P <.; e P <. compared to P/R Control f late relapser after follow-up week 24, not included n SVR. 75 e P/R/B P/low dose R/B 48 wks 48 wks N=6 N=59 SPRINT-: Boceprevir + PegIFN/RBV in Null Responders to SOC IDEAL study found log decrease in HCV RNA at Wk 4 of pegifn alfa-2b associated with ~ 2 log decrease at Wk 2 [] Two 4-wk lead-in arms of pegifn alfa-2b allowed determination of likely virologic response to SOC [2] Definition of a null response to pegifn alfa-2b : < log decrease at Wk 4 <.5 log drop at Wk 4 of pegifn/rbv lead-in to <. log 6 drop at Wk 4 of 44 pegifn/rbv lead-in /7 5/2 4/9 8/3 PegIFN/RBV 4 wks PegIFN/RBV 4 wks PegIFN/RBV/Boceprevir PegIFN/RBV/Boceprevir SVR (%). McHutchison JG, et al. N Engl J Med. 29;36: Kwo PY, Lancet 2 3
4 Treatment of previous PEG/RBV nonresponders with protease inhibitors Those who are previously interferon sensitive have high chance of achieving SVR (relapsers) Null responders will have opportunity for SVR but with significant risk of developing resistance Treating clinicians will need to counsel genotype infected individuals about risks benefits Advanced fibrosis Stopping rules to minimize resistance More Drugs = More Toxicity Cardiotoxicity Optic neuritis Rash Anemia Neutropenia Lymphopenia Liver test abnormalities DC rates x 2-4 fold Phase 3 Results to be reported at AASLD Telaprevir Advance trial: 75%; Illuminate: 72% treatment naïve Realize: 66% treatment failures Boceprevir Sprint 2: 66% treatment naïve Respond 2: 66% treatment failures HCV RNA Polymerase Nucleoside and Non-nucleoside Inhibition Fingers NNI Allosteric GTP-binding sites Flap Thumb Thumb inhibitors Catalytic site Nucleoside analogs Palm NNI Adapted from Butcher. Nature. 2;4:235. Reprinted with permission. Can We Dispense with Ribavirin? R728 (Nucleoside Polymerase Inhibitor) demonstrated 2.7 log (>99%) Mean HCV RNA Decrease with 5 mg BID Dose Prove 2 (n = 334) Prove 3 (n = 453) All studies showed Sprint (n = 595) Lower response rates w/o ribavirin Higher viral breakthrough rates Mean HCV RNA Change from Baseline N=8 interferon failures per cohort Treatment Period Placebo (-. log IU/ml) 75 mg QD (-.9 log IU/ml) 5 mg QD (-.5 log IU/ml) 75 mg BID (-2. log IU/ml) 5 mg BID (-2.7 log IU/ml) Period Study Day Hezode C, et al. New Engl J Med. 29;36(8): McHuthcison et al NEJM 29. Kwo P, et al. Lancet 2. No Evidence of Viral Rebound During 4 Days of Monotherapy Source: Reddy. Abstract #LB-9. AASLD 27. 4
5 Phase Combination Data with R728 Nucleoside Polymerase Inhibitor % PCR neg % P+R 28 Day Data 3% P+R+R728 5 mg bid 85% P+R+R728 5 mg bid Mean log decline McHutchison. EASL 28 INFORM-: 4-Day Response Rates in Tx-Naive and Tx-Experienced G HCV Pts New data at higher dose AASLD R728/R7227 Doses, mg n Pt Population Median Change From Baseline, Log IU/mL HCV RNA < LLOQ, % < 4 IU/mL < 5 IU/mL 5/ TID 8 Naive /2 TID 8 Naive / TID 7 Naive /2 TID 8 Naive /9 BID 8 Naive /6 BID 8 Exp, nonnull /9 BID 8 Exp, null No serious adverse events, treatment-related discontinuations, or grade 3/4 laboratory abnormalities observed in any treatment arm Gane EJ, No et evidence al. AASLD of 29. emergent Abstract drug 93. resistance during treatment Mean Decline in HCV RNA 24 Hours After Single Dose of NS5a inhibitor BMS mg mg mg -.8 (Range.8-3. log ) (Range log ) (Range log ) mg dose: mean in HCV RNA of 3.6 log IU/mL (range log IU/mL) at 48 hours after maintained at 44 hours All active drug recipients had.5 log from baseline HCV RNA 8/6 (5%) active drug recipients had 3 log IU/mL in HCV RNA One active drug recipient achieved HCV RNA < LLQ Nettles et al. AASLD. October 3-November 4, 28; San Francisco, CA. Poster LB2. Conclusions Addition of telaprevir and boceprevir to Peg interferon/ ribavirin will improve SVR rates significantly Treatment durations weeks Phase 3 results to be reported AASLD 2 Non-responders will also derive benefit with risk of resistance, relapsers can be treated with low risk Greater side effects Combinations of DAA/STAT-C C agents with/without PEG IFN/RBV will explored Trials to achieve SVR without interferon/ribavirin The future is bright INFORM-: Dual Polymerase and Protease Inhibitors R728 and R7227 For HCV Genotype Day 4 Day 7 Day 4 Wk 48 RG728 5 mg BID + RG7227 mg TID RG728 5 mg BID + RG mg TID (n = 8 active, placebo) Treatment naive RG728 mg BID + RG7227 mg TID (n = 8 active, placebo) RG728 mg BID + RG mg TID Pts infected (n = 8 active, 4 placebo) with G HCV RG728 mg BID + RG mg BID (N = 86)* Previous nonresponders RG728 mg BID + RG mg BID to IFN (excluding null responders) Previous null RG728 mg BID + RG mg BID responders to IFN *2 additional arms not included in current analysis. PegIFN, peginterferon alfa-2a 8 μg/wk; RBV, ribavirin -2 mg/day. Gane EJ, et al. AASLD 29. Abstract 93. 5
Hepatitis C Therapy Falk Symposium September 20, 2008
Hepatitis C Therapy Falk Symposium September 20, 2008 Ira M. Jacobson, MD Vincent Astor Professor of Clinical Medicine Chief, Division of Gastroenterology and Hepatology Medical Director, Center for the
More informationHow to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy
How to optimize current therapy for GT1 patients Shortened therapy with IFNa-based therapy Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationABCs of Hepatitis C: What s New. The Long-Awaited New Era: Protease Inhibitors for HCV Genotype 1
ABCs of Hepatitis C: What s New ACG Postgraduate Course Washington, DC October 30, 2011 Ira M. Jacobson, M.D. Vincent Astor Professor of Medicine Chief, Division of Gastronterology and Hepatology Medical
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationNew Therapeutic Strategies: Polymerase Inhibitors
New Therapeutic Strategies: Polymerase Inhibitors 6th Paris Hepatitis Conference 14 th - 15 th January, 2013 Stefan Zeuzem Goethe University Hospital Frankfurt, Germany Direct antiviral targets C E1 E2
More informationةي : لآا ةرقبلا ةروس
سورة البقرة: اآلية HCV RELAPSERS AND NONRESPONDERS: How to deal with them? BY Prof. Mohamed Sharaf-Eldin Prof. of Hepatology and Gastroenterology Tanta University Achieving SVR The ability to achieve a
More informationHepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors
Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationHepatitis C Treatment 2014
Hepatitis C Treatment 214 Brendan M. McGuire, MD UAB Liver Center Outline Epidemiology/National History Terminology for Treatment Treatment Considerations Current Treatment Options Genotype 1 (GT 1) Genotype
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More informationTratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona
Tratamiento de la Hepatitis C Rafael Esteban Hospital General Universitario Valle de Hebrón Barcelona rrent HCV Therapy 8% % sustained response 6% 4% 2% % 54-61% 41% 34% 25% 16% 6% IFN 24w IFN 48w Peg
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationAssociate Professor of Medicine University of Chicago
Nancy Reau, MD Associate Professor of Medicine University of Chicago Management of Hepatitis C: New Drugs and New Paradigms HCV is More Lethal than HIV Infection HCV superseded HIV as a cause of death
More informationLes Inhibiteurs de Protéase du VHC
Les Inhibiteurs de Protéase du VHC Pr Jean-Michel Pawlotsky National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital University of Paris-Est
More informationClinical Management: Treatment of HCV Mono-infection
Clinical Management: Treatment of HCV Mono-infection Curtis Cooper, MD, FRCPC Associate Professor-University of Ottawa The Ottawa Hospital- Infections Diseases Viral Hepatitis Program- Director Industry
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationClinical Cases Hepatitis C Naïve Patients. Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona.
Clinical Cases Hepatitis C Naïve Patients Rafael Esteban Liver Unit. Hospital General Universitari Vall Hebron. Barcelona. Case study 1 27 year old woman, Diagnosed with Chronic Hepatitis C 3 years ago
More informationHCV MEDICATIONS & Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati
HCV MEDICATIONS & THERAPEUTIC TRIALS Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati DISCLOSURES Active or Within 12 Months Research
More informationHepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors
Hepatitis C: Management of Treatment Naïve Patients with First Line Protease Inhibitors Eric Lawitz, MD, AGAF, CPI The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science
More informationInterferon-based and interferon-free new treatment options
Interferon-based and interferon-free new treatment options White Nights of Hepatology St. Petersburg, 7. June 2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Medizinische Klinik I Frankfurt
More informationBest of AASLD 2010 For IAGH. April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS
Best of AASLD 2010 For IAGH April 2011 Reza Malekzadeh M.D. AGAF Professor of Medicne DDRC/TUMS DAAs Direct-Acting Antivirals Understanding of HCV life cycle Identification of potential targets of antivirals
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationSpecifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C
Specifically Targeted Antiviral Therapy (STAT-C) for Patients With Chronic Hepatitis C Zobair M. Younossi, MD, MPH, FACP, FACG Medscape Gastroenterology. 2007; 2007 Medscape Posted 06/01/2007 Introduction
More informationTreating HCV Genotype 2 & 3
Treating HCV Genotype 2 & 3 3rd Workshop on HCV Therapy Advances, Rome 14.12.2013 Christoph Sarrazin Klinikum der J. W. Goethe-Universität Frankfurt am Main, Germany HCV Genotypes 2 & 3 Laurel and Hardy
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationChanging Direction Towards More Effective HCV Treatment
Changing Direction Towards More Effective HCV Treatment By: Prof.Dr.Abdel fattah Hanno Professor of Tropical Medicine Alexandria Faculty of Medicine The most common disease in the world HCV infects almost
More informationHepatitis C Emerging Treatment Paradigms
Hepatitis C Emerging Treatment Paradigms David R Nelson MD Assistant Vice President for Research Professor of Medicine Director, Clinical and Translational Science Institute University of Florida Gainesville,
More informationVirological Tools and Monitoring in the DAA Era
Virological Tools and Monitoring in the DAA Era Prof. Jean-Michel Pawlotsky, MD, PhD National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationInterferon Side Effects and The Future of Interferon Sparing Regimens. Todd Wills, MD ETAC Infectious Disease Specialist
Interferon Side Effects and The Future of Interferon Sparing Regimens Todd Wills, MD ETAC Infectious Disease Specialist HEPATITIS C TREATMENT EXPANSION INITIATIVE MULTISITE CONFERENCE CALL FEBRUARY 15,
More information47 th Annual Meeting AISF
47 th Annual Meeting AISF Rome, 21 February 2014 Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations (HCV/HIV coinfection, advanced cirrhosis,
More informationVII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES
VII CURSO AVANCES EN INFECCIÓN VIH Y HEPATITIS VIRALES REGIMENES TERAPÊUTICOS DE LA HEPATITIS C, INTERFERÓN FREE A Coruña 2 Febrero 2013 Rui Sarmento e Castro Centro Hospitalar do Porto HJU ECS Universidade
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationCase #1. Case #1. Case #1: Audience vote VS. The Great Debate: When to Treat HCV in our HIV coinfected patients
Case #1 The Great Debate: When to Treat HCV in our HIV coinfected patients Medical Management of AIDS December, 2012 Moderated by George Beatty,MD 35 year old African American man, CD4 + 450, HIV RNA
More informationASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT
ASSAYS UTILZIED TO MONITOR HCV AND ITS TREATMENT Mitchell L Shiffman, MD Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA Liver Institute of Virginia Education, Research
More informationInfection with hepatitis C virus (HCV) is a global health concern,
Advances in the Treatment of Hepatitis C Virus Infection Arun B. Jesudian, MD, Maya Gambarin-Gelwan, MD, and Ira M. Jacobson, MD Dr. Jesudian is a Clinical Fellow, Dr. Gambarin-Gelwan is an Assistant Professor
More informationEvolution of Therapy in HCV
Hepatitis C: Update on New Therapies and AASLD 13 David Bernstein, MD, FACP, AGAF, FACP Professor of Medicine Hofstra North Shore-LIJ School of Medicine Evolution of Therapy in HCV 199 1999 1 13 (%) SVR
More informationCURRENT TREATMENTS. Mitchell L Shiffman, MD Director Liver Institute of Virginia. Richmond and Newport News, VA, USA
CURRENT TREATMENTS FOR HCV Mitchell L Shiffman, MD Director Liver Institute of Virginia Bon Secours Health System Richmond and Newport News, VA, USA Liver Institute of Virginia Education, Research and
More informationOptimal Treatment with Boceprevir. Michael Manns
Optimal Treatment with Boceprevir Michael Manns 6th Paris Hepatitis Conference, 14th January 2013 Acknowledgements Benjamin Maasoumy Optimal Patient Selection Defining the Ideal Candidate Treatment Urgency
More informationAntivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond
Antivirals for the treatment of chronic HCV infection: Bench to Bedside and beyond Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Baltimore, Maryland Disclosures for
More informationThe Pipeline of New HCV Therapies: What to Expect in the Next 5 Years. Nancy Reau, MD Associate Professor University of Chicago
The Pipeline of New HCV Therapies: What to Expect in the Next 5 Years Nancy Reau, MD Associate Professor University of Chicago Learning Objectives Upon completion of this presentation, learners should
More informationEASL and The Future of HCV Treatment
EASL and The Future of HCV Treatment Douglas T. Dieterich, M.D Professor of Medicine Division of Liver Diseases, Gastroenterology and Infectious Diseases Department of Medicine Mount Sinai School of Medicine
More informationSignificance of Hepatitis C. The Evolving Burden of Hepatitis C. The Bad News... The Good News... Chronic Hepatitis C Can be Cured
Journée scientifique de l'arl Yverdon, 24 mars 2011 Darius Moradpour Service de Gastroentérologie et d'hépatologie Centre Hospitalier Universitaire Vaudois Université de Lausanne Significance of Hepatitis
More informationTriple therapy with telaprevir or boceprevir: management of side effects
Triple therapy with telaprevir or boceprevir: management of side effects Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationMany promising small molecule inhibitors directed
GASTROENTEROLOGY 2012;142:1351 1355 Will Interferon-Free Regimens Prevail? Christoph Welsch Stefan Zeuzem Department of Internal Medicine I, J. W. Goethe University Hospital, Frankfurt/Main, Germany Many
More informationExperience with pre-transplant antiviral treatment: PEG/RBV and DAA. Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona
Experience with pre-transplant antiviral treatment: PEG/RBV and DAA Xavier Forns, MD Liver Unit Hospital Clínic IDIBAPS and CIBREHD Barcelona Interferon-free regimens G1b nulls Asunaprevir (PI) + Daclatasvir
More informationHepatite crônica C. Novos tratamentos. Prof. Henrique Sergio Moraes Coelho. III Workshop Internacional de Atualização em Hepatologia
Hepatite crônica C Novos tratamentos Prof. Henrique Sergio Moraes Coelho III Workshop Internacional de Atualização em Hepatologia Abril de 2008 Curitiba-Paran Paraná Hepatology 2004 56-61 Real-World SVR
More informationHighlights of AASLD 2012 CCO Official Conference Coverage of the 2012 Annual Meeting of the American Association for the Study of Liver Diseases
Highlights of AASLD 12 CCO Official Conference Coverage of the 12 Annual Meeting of the American Association for the Study of Liver Diseases November 9-13, 12 Boston, Massachusetts In partnership with
More informationStrategies towards cure of HCV infection: a personalized approach. Heiner Wedemeyer Hannover Medical School Hannover, Germany
Strategies towards cure of HCV infection: a personalized approach Heiner Wedemeyer Hannover Medical School Hannover, Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years): Abbott, Biolex,
More informationManagement of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy?
Management of CHC G1 patients who are relapsers or non-responders to Peg IFN and RBV therapy: Wait or Triple Therapy? Prof. Teerha Piratvisuth NKC Institute of Gastroenterology and Hepatology Prince of
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More information29th Viral Hepatitis Prevention Board Meeting
29th Viral Hepatitis Prevention Board Meeting Madrid, November 2006 Treatment of chronic hepatitis C José M. Sánchez-Tapias Liver Unit Hospital Clínic University of Barcelona Spain CHRONIC HEPATITIS C
More informationHCV Resistance Associated variants: impact on chronic hepatitis C treatment
HCV Resistance Associated variants: impact on chronic hepatitis C treatment Dr. Stéphane Chevaliez Associate Professor of Medicine at the University of Paris-Est. History of Resistance in HCV Concern Only
More informationPersonalised Treatment with Telaprevir in Graham R Foster Professor of Hepatology Queen Marys University of London
Personalised Treatment with Telaprevir in 2014 Graham R Foster Professor of Hepatology Queen Marys University of London Telaprevir in 2014 Disclaimers I have received funds from: BI, BMS, Janssen, Novarts,
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationNew Antiviral Therapy for HCV: Progress Toward Cure
New Antiviral Therapy for HCV: Progress Toward Cure Raymond T. Chung, MD Director of Hepatology Vice Chief, GI Unit MGH Worldwide Prevalence of HCV HCV Genomic Organization 5 UTR region 9.6 kb RNA 3 UTR
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationHepatitis C: Aplicaciones Clínicas de la Resistencia. Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña
Hepatitis C: Aplicaciones Clínicas de la Resistencia Eva Poveda Division of Clinical Virology INIBIC-Complexo Hospitalario Universitario de A Coruña DAA agents approved or in more advanced stages of clinical
More informationPegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C
Liver International ISSN 1478-3223 REVIEW ARTICLE Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C Nicole M. Welch and Donald M. Jensen University
More informationHCV: Racial Disparities. Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD
HCV: Racial Disparities Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Research Grants Boehringer Ingelheim, Inc.
More informationClinical Applications of Resistance Stuart C. Ray, MD
Clinical Applications of Resistance Stuart C. Ray, MD Professor of Medicine and Oncology Director, Infectious Diseases Fellowship Training Program Johns Hopkins University School of Medicine Disclosures
More informationUpdate on the Treatment of HCV
Update on the Treatment of HCV K. Rajender Reddy, MD Professor of Medicine Director of Hepatology Director, Viral Hepatitis Center University of Pennsylvania Philadelphia, USA 1 K. Rajender Reddy, MD Disclosure
More informationHepatitis C Virus Treatments: Present and Future
Hepatitis C Virus Treatments: Present and Future Charles D. Howell, M.D., A.G.A.F Professor of Medicine University of Maryland School of Medicine Baltimore, MD Charles Howell Disclosures Boehringer Ingelheim,
More informationBackground: Narlaprevir (SCH )
Once Daily Narlaprevir (SCH 9518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study Vierling J,
More informationTreatment of chronic hepatitis C in drug-naïve patients
Treatment of chronic hepatitis C in drug-naïve patients 8th International Workshop on HIV & Hepatitis Co-infection Madrid, 31. May 2012 Christoph Sarrazin J. W. Goethe-University Hospital Medizinische
More informationFuture HCV Treatment: Interferon-sparing. Ed Gane NZ Liver Transplant Unit
Future HCV Treatment: Interferon-sparing Combination DAA therapy Ed Gane NZ Liver Transplant Unit % SV VR (cure e) Protease Inhibitor plus Peg-IFN/RBV Triple Therapy in Treatment-Naïve Gt1 ADVANCE p Phase
More informationTreatement Experienced patients without cirrhosis. Rafael Esteban Hospital Universitario Valle Hebron Barcelona
Treatement Experienced patients without cirrhosis Rafael Esteban Hospital Universitario Valle Hebron Barcelona Agenda With IFN PegIFN+ Ribavirin + Simeprevir PegIFN+ Ribavirin+ Sofosbuvir Without IFN Sofosbuvir
More informationTreatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies. Advances in treatment of HCV Dr John F Dillon
Treatment Targets HCV Genotype 1 & PIs Treating HCV G2&3 Future Therapies Advances in treatment of HCV Dr John F Dillon Disclosure slide I have received consulting fees and Honoraria from MSD, Abbott,
More informationUpdates on Current Status of HCV Therapy
Updates on Current Status of HCV Therapy K. Rajender Reddy, MD Professor of Medicine, Professor of Medicine in Surgery, Director of Hepatology and Medical Director of Liver Transplantation University of
More informationNew Treatments for Chronic Hepatitis C. Rafael Esteban Hospital Valle Hebron. Barcelona Spain
New Treatments for Chronic Hepatitis C Rafael Esteban Hospital Valle Hebron. Barcelona Spain The present: a complex treatment with a better SVR Genotype 1 Genotypes 2 and 3 Triple therapy Boceprevir (BOC)
More informationBristol-Myers Squibb. HCV Full Development Portfolio Overview. Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013
Bristol-Myers Squibb HCV Full Development Portfolio Overview Richard Bertz Int Workshop CP HIV Meeting Amsterdam, Netherlands 24 April 2013 1 BMS Agents in Clinical Development: DAAs and INF Lambda Lambda
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) Goals for Hepatitis C Therapy Compared to PegIFN α/rbv, new treatment regimens for chronic hepatitis C should offer: Improved efficacy Efficacy
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationPredictors of Response to Hepatitis C Therapy in the DAA Era. Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid
Predictors of Response to Hepatitis C Therapy in the DAA Era Pablo Barreiro Servicio de Enfermedades Infecciosas Hospital Carlos III, Madrid Why Predicting HCV Response? Select candidates for therapy Prioritizing
More informationCurrent Treatments for HCV
Current Treatments for HCV Mitchell L. Shiffman, MD, FACG Advisory Committee/Board Member: Achillion, Anadys, Boehringer-Ingelheim, BMS, Conatus, Genentech, Gen-Probe, Gilead, Globeimmune, GSK, Janssen,
More informationHCV-G3: Sofosbuvir with ledipasvir or daclatasvir?
HCV-G3: Sofosbuvir with ledipasvir or daclatasvir? Ioannis Goulis, MD Aristotelian University of Thessaloniki XXIII International Hepatitis B & C Meeting of Athens Hadziyannis HCV genotype 3 therapy Chronic
More informationCombination therapy with pegylated interferon (PEG-
Editorials Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet? See Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 2)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 2) PegIFN and RBV remain vital components of HCV therapy-- selected presentations from: Program Disclosure This activity has been planned and
More informationNS5A inhibitors: ideal candidates for combination?
NS5A inhibitors: ideal candidates for combination? Professor Vasily Isakov, MD, PhD, AGAF Dep.Gastroentrology & Hepatology, ION, Russian Academy of Sciences, Moscow Structure and function of NS5A Meigang
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationSAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano
SAVINO BRUNO, MD Director Internal Medicine and Hepatology Unit AO Fatebenefratelli e Oftalmico, Milano Market wheretelaprevir has not yet launched Victrelis is still launching January 29 th 214 Developed
More informationAzienda ULSS12 Veneziana
Azienda ULSS12 Veneziana Risultati del trattamento dei monoinfetti con Sofosbuvir, Simeprevir nella coorte veneziana. Confronto di esito con la coorte del trattamento con Boceprevir e Telaprevir Dr.ssa
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationClinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient. Konstantin Zhdanov
Clinical Сase A previously relapse to PEG IFN + RBV in HCV G3a patient Konstantin Zhdanov Genotype 3 in Europe Canada Norway Germany Sweden Czech Republic Poland Approximately 1/3 of HCV-infected patients
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationHIV and Hepatitis C: Advances in Treatment
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV and Hepatitis C: Advances in Treatment John Scott, MD, MSc Asst Professor University of Washington Presentation prepared & presented by: John Scott, MD,
More informationEmerging Therapies for HCV: Highlights from AASLD 2012 (Part 1)
Emerging Therapies for HCV: Highlights from AASLD 2012 (Part 1) Goals for Hepatitis C Therapy Compared to PegIFN/RBV, new products should offer: Improved efficacy Efficacy in all patient types including
More informationFeeling right at home
Feeling right at home Getting to Cure From Cure to Eradication Jordan J. Feld MD MPH Toronto Centre for Liver Disease Sandra Rotman Centre for Global Health University of Toronto SVR Dramatic Improvements
More information